Weight Effects of Wellbutrin and Zoloft
No, Wellbutrin (bupropion) does not cause weight gain—it consistently promotes weight loss—while Zoloft (sertraline) is weight-neutral with long-term use. 1, 2
Wellbutrin (Bupropion): Weight Loss Effect
Bupropion is the only antidepressant that consistently causes weight loss by suppressing appetite and reducing food cravings through its norepinephrine and dopamine reuptake inhibition mechanism 1, 2. The FDA-approved drug label confirms this effect with clinical trial data:
- 14-19% of patients lost >5 lbs on bupropion sustained-release (300-400 mg/day) compared to only 6% on placebo 3
- 23% of patients lost ≥5 lbs on bupropion extended-release in seasonal affective disorder trials versus 11% on placebo 3
- Only 2-3% gained >5 lbs compared to 4% on placebo 3
A 2024 large-scale electronic health record study of 183,118 patients found bupropion resulted in 0.22 kg less weight gain at 6 months compared to sertraline, with a 15% reduced risk of gaining ≥5% of baseline weight 4.
Zoloft (Sertraline): Weight-Neutral Profile
Sertraline demonstrates a biphasic weight pattern: initial weight loss during acute treatment (4-12 weeks) followed by weight neutrality with long-term maintenance (>4 months) 1, 2. This makes it one of the preferred SSRIs when weight concerns exist.
The 2015 Endocrine Society Clinical Practice Guideline specifically states that "SSRIs such as fluoxetine and sertraline have been associated with weight loss during acute treatment and with weight neutrality in the maintenance phase" 2. This contrasts sharply with paroxetine, which carries the greatest long-term weight gain risk among SSRIs 2.
Clinical Implications
When weight is a concern:
- Choose bupropion if the patient's depression profile allows (not appropriate for bipolar disorder or severe anxiety due to its activating properties) 1
- Sertraline is an excellent alternative when bupropion is contraindicated, as it remains weight-neutral long-term 1, 2
- Avoid paroxetine, which has the highest weight gain potential among SSRIs 1, 2
Important caveat: Bupropion's activating properties can exacerbate anxiety or be inappropriate for bipolar disorder, so medication selection must balance weight effects against psychiatric indication 1. However, when clinically appropriate, bupropion offers the dual benefit of treating depression while promoting modest weight loss—even receiving FDA approval for chronic weight management in combination with naltrexone (Contrave) in 2014 1.
The evidence is particularly strong because it comes from multiple high-quality guidelines (2017 Gastroenterology, 2015 Endocrine Society) 1, 2, FDA drug labeling data 3, and recent large-scale observational studies 4, all consistently showing the same pattern.